2012 came and went, leaving many investors and emerging growth biotechs still waiting for the opportunities promised in the Jumpstart Our Business Start-ups (JOBS) Act, as the SEC has missed its deadlines for implementing major provisions of the legislation, which was passed last year to provide new fundraising options and ease the burden of complying with securities laws. Read More
Theravance Inc., of South San Francisco, will use proceeds of a $250 million aggregate principal amount of convertible subordinated notes due 2023 to make milestone payments to GlaxoSmithKline plc upon launch of products developed under the two companies' collaboration around long-acting beta 2 agonists (LABAs). Read More
The Pharmaceutical Research and Manufacturers of America (PhRMA) served up two reports Thursday touting U.S. biopharma's "innovative and robust" pipeline of some 5,400 new molecular entities (NMEs), including more than 800 in Phase III studies. Read More
• Collegium Pharmaceutical Inc., of Canton, Mass., said it relocated its lab facilities and corporate offices from Cumberland, R.I., to Massachusetts. Read More
• Astex Pharmaceuticals Inc., of Dublin, Calif., is launching a Phase I trial of AT13148, a drug designed to block enzymes controlling cancer cell growth and death. Read More
• Laboratoires Pierre Fabre Dermatologie, of Castres, France, a subsidiary of Laboratoires Pierre Fabre, and Maruho Co. Ltd., of Osaka, Japan, inked a licensing deal to develop and market in Japan an oral formulation of a pediatric beta-blocker for the treatment of infantile hemangioma requiring a systemic therapy. Read More
• Cancer Research UK's Drug Development Office in London and partner AstraZeneca plc, of London, opened a three-armed study testing AZD0424 in a Phase I trial expected to recruit up to 30 patients, initially across all solid tumor types. Read More
• Lithera Inc., of San Diego, was issued a notice of allowance for its U.S. patent application, related to LIPO-202 (Salmeterol Xinafoate for Injection). LIPO-202 is being developed for selective, nonablative, local fat reduction. Read More
